1,25(OH)2D3 and Cyclooxygenase-2: Possible Targets for Breast Cancer? by M. Thill et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
31 
1,25(OH)2D3 and Cyclooxygenase-2:  
Possible Targets for Breast Cancer? 
M. Thill1, S. Becker1, D. Fischer1, K. Diedrich1, D. Salehin2 and M. Friedrich2 
1Department of Obstetrics and Gynecology, University Schleswig-Holstein,  
Campus Luebeck, Luebeck 
2Department of Gynecology and Obstetrics, Helios Hospital Krefeld,  
Krefeld 
Germany 
1. Introduction 
Currently, breast cancer is the most common malignancy in women. In the U.S. in 2005, 
approximately 211.240 patients were newly diagnosed with primary breast cancer and 
58.490 women were diagnosed with ductal carcinoma in situ (DCIS). Of these, 58.490 deaths 
are estimated. Therefore breast cancer takes second place following only behind lung cancer 
[1,2,3]. Because of this, it is necessary to develop new strategies and treatment options that 
may improve the prognosis. 
Besides the classic histo-pathological parameters used to estimate the prognosis of 
malignant diseases, the identification of additional molecular prognostic parameters would 
be very helpful in planning treatment by evaluating protein or mRNA expression in tumor 
tissue. One of these potential molecular prognostic parameters might be the cyclooxygenase-
2 (COX-2) [4, 5]. New treatment strategies using compounds that attack well defined 
proteins in the tumor require verification of the expression of these target proteins. Many 
similarities exist between tumor tissue and inflammatory modified tissue and normally, 
inflammatory reaction is self limiting, however, in tumor tissue the inflammatory reaction is 
persistent. An increased angiogenesis and an elevated production of cytokines, chemokines 
and proteases lead to good conditions for cell proliferation and invasion in the tumor tissue 
[6]. 
Targeted strategies might eliminate this inflammatory reaction that promotes tumor growth 
and tumorigenesis and there is already promising data around the use of COX-2-inhibitors. 
The antiproliferative effects of vitamin D may be another starting point; however the data 
on vitamin D intake or to the exertion of vitamin D analogs is occasionally inconsistent.  
The important role that vitamin D and calcium adopt in the human metabolism was 
recognized as early as the nineteen-twenties as it was used to prevent the bone disease, 
rickets which was widespread in children at that time [7]. In the last 20 years non-classical 
effects of vitamin D and its influence on physiology followed because it’s potentially 
anticarcinogen impacts made it more and more interesting. Besides stable calcium-
homeostasis by the renal expressed 1-α-hydroxylase functionality, extra renal expressed 1-α-
hydroxylase also is also known to have antiproliferative and immune-modulating features 
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[8-10]. This fact has led to the development of new treatment strategies in the clinical use of 
1,25(OH)2D3 (calcitriol). The goal was to affect and treat cancer, psoriasis, autoimmune 
diseases and host-graft-rejection [11-14]. Implementation of these new treatment options in 
vivo was conspicuously hindered as 1,25(OH)2D3 has a potentially hypercalcaemic side 
effect. Finally the application of synthetic 1,25(OH)2D3 analogs led to several successful 
results due to its less calciotropic effects [15, 16]. The implementation of vitamin D, 
primarily cancer and autoimmune diseases appears to play a more preventative role as 
opposed to therapeutic [17, 18]. 
Observational studies showed an association between vitamin D intake and 25(OH)2D3 
plasma levels as well as a reduced risk of breast cancer [19, 20]. Studies that tried to 
elucidate the correlation between sunlight and cancer prevention demonstrated that long 
sunlight exposure was associated with a low rate of primary breast cancer and consecutively 
a low mortality rate [21-24]. 1,25(OH)2D3 is the biologically active form of vitamin D that 
binds as a ligand to the nuclear vitamin D receptor (VDR) of the genes that are important for 
vitamin D metabolism (1-α-hydroxylase, 24-hydroxylase) [25]. 1,25(OH)2D3 and its analogs 
are able to inhibit the proliferation of breast cancer cells in vitro and in vivo [26-29]. 
2. Prostaglandin metabolism 
The cyclooxygenase system consists of two different isoenzymes, COX-1 and COX-2. This 
system is an integral part of the prostaglandin syntethase complex and is involved 
controlling inflammatory processes (1). After transformation of arachidonic acid to 
prostaglandin G2 (PGG2), a glutathione dependent peroxidase converts PGG2 to PGH2 by an 
oxi- and peroxidation. PGH2 acts as basic substrate for the synthesis of different 
prostaglandins by the microsomal and cytosolic prostaglandin synthase, which are tissue- 
and cell-specific. Based on the cellular enzyme setting, different prostaglandins are 
synthesized in different tissues where they act in an auto- or paracrine manner [30]. 
Prostaglandin E2 (PGE2) is one of the best known prostaglandins and is generated by the 
prostaglandin E synthase. These consist of three different forms: two microsomal 
prostaglandin E synthases and the cytosolic prostaglandin synthase E [31]. 
The 15-hydroxyprostaglandin dehydrogenase (15-PGDH) belonging to the oxidoreductases 
family, inactivates all generated prostaglandins by oxidation to 15-keto metabolites which 
then have greatly reduced biological activity [32]. 
3. PG-receptors 
The physiological effects of many prostaglandins are mediated by binding to G protein 
coupled receptors. These effects regulate inflammatory mediations, control hormone 
regulation, constrict or dilate in vascular smooth muscle cells and regulate calcium 
movement and their specific receptors activate signal transduction pathways which could 
induce chronic processes like angiogenesis. For example, PGE2 interacts with four cell 
surface receptors - EP1-4 and the EP2 receptor subtype is involved in the 
Gs/cAMP/proteinkinase which is a-signalling pathway leading to an increased VEGF 
expression. PGJ2 and PGA2 interact with nuclear receptors, belonging to the peroxisome 
proliferator-activated receptors (PPARs) family. After dimerization with the 9-cis-Retinoid 
receptor (RXR) and then binding to a sequence specific responsive element located at the 
promoter of its target gene, they directly induce gene expression [33]. 
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Fig. 1. Prostaglandin metabolism. 
4. Isoenzymes COX-1 und COX-2 
COX-1 is ubiquitary and not a relevant prognostic factor [34]. In contrast, the COX-2 enzyme 
is not constitutively expressed. The COX-2 gene expression is stimulated by many growth 
factors, cytokines and prostaglandins and is associated with inflammation [35]. COX-2 is 
predominantly a pro inflammatory enzyme but late in the inflammatory phase, the enzyme 
is involved in limiting inflammation. 
Studies with COX-1 and COX-2 knockout mice lead to new consolidated findings about the 
function of these enzymes concerning ovarian functionality and reproduction as well as 
cardiovascular development [36 - 39]. The COX enzymes are the main target of non-steroidal 
anti inflammatory drugs (NSAID) where isoenzymes specifically inhibit the biological activity 
of COX enzymes. Celecoxib and rofecoxib are selective COX-2 inhibitors whereas 
acetylsalicylic acid, ibuprofen and indomethacin are non-specific and target both isoenzymes.  
5. Role of COX-2 in carcinogenesis 
The cyclooxygenases, especially COX-2, play an important role in the development and 
progression of malignant tumours. The over expression of COX-2 is associated with the 
differentiation of tumor cells by several mechanisms [40] and can be detected in various 
epithelial carcinomas such as in colon [41, 42], gastric [43] and esophageal cancers [44] as 
well as in prostate [45], liver, pancreas and lung cancers [46]. One of the mechanisms that 
are modulated during carcinogenesis is the neoangiogenesis [47 – 55].  
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Epidemiological studies have shown that a continuous intake of NSAIDs protects against 
the incidence of breast cancer [56-58]. 
Increased PGE2 levels can be detected in cultivated human breast cancer cell lines as well as 
in invasive human breast cancer cells [59-62] and are associated with both a negative 
hormone receptor status and an escalated mestastic potential [59]. 
As mentioned previously, PGE2 is the ligand for at least four cell surface receptors - EP1-4 
and several studies have presented the impact of the EP1-receptor in carcinogenesis of colon 
and breast cancer [63]. A blockage of the EP2-receptor leads to a reduction and a 
diminishment of intestinal polyposis in APC∆716-knock-out mice [64]. There was an 
increased detection of EP2- and EP4-receptors in the breast tumors of COX-2-MMTV mice; 
therefore, it appears that the EP-receptors play an important role in mediating PG functions 
and in promoting carcinogenesis. 
6. Role of 15-PGDH in carcinogenesis 
Increased PGE2 levels in context to mammary carcinomas are associated with an enhanced 
cell proliferation, invasiveness, resistance to apoptosis and angiogenesis [65, 66]. The 
regulation of plasma PGE2 level results from its synthesis and its biological inactivation 
through 15-PGDH, the key enzyme for the biological inactivation of PGs [32]. Recent studies 
hypothesized 15-PGDH as a tumor suppressor gene in correlation to colon, bladder and 
bronchial carcinomas [67-69]. Wolf and co-workers [70] assumed antiproliferative effects of 
15-PGDH in breast cancer cells. The estrogen receptor (ER) positive and well differentiated 
MCF-7 breast cancer cell line had an increased 15-PGDH expression compared to poorly 
differentiated, ER negative MDA-MB-231 cells, which express COX-2 and lead to primary 
breast cancer. Different studies reported that MCF-7 cells are the only breast cancer cell line 
with an enhanced 15-PGDH expression and low levels of 15-PGDH are accompanied by 
poorly prognostic factors [70]. This data attended by a microarray analysis of van’t Veer and 
co-workers [71] supports the advice that a loss of 15-PGDH expression plays a pivotal role 
in the development of poorly differentiated mammary carcinomas. Data generated from 
genetically modified MDA-MB-231 cells that over express the enzyme and MCF-7 where 15-
PGDH was knockout, corroborates the hypothesis that 15-PGDH acts as a tumor suppressor 
gene in breast cancer [70]. MDA-MB-231 cells showed a decreased invasiveness similar to 
studies in colon [67] and bronchial carcinomas [68]. Yan and co-workers [67] reported that 
15-PGDH is naturally expressed in colon tissues and was dramatically reduced in colon 
carcinomas. The reconstitution of 15-PGDH in immunodeficiency mice prevented the colon 
cancer cells from generating tumors and so the authors concluded, that 15-PGDH acts as 
tumor suppressor and inhibits the angiogenic and proliferative effects of COX-2 in vivo. 
7. COX-2 expression in breast cancer 
Experimental immunochemical studies of COX-2 expression in breast cancer have produced 
varying and sometimes controversial and inconsistent data. Generally the consensus is that 
COX-2 is expressed by invasive ductal and lobular carcinoma and that the proportion of 
COX-2 positive tumors varies between studies (Table 1). In studies where poor prognostic 
tumor characteristics were examined, a correlation was found between prognostic 
parameters such as hormone receptor negativity, HER2 positivity, increased tumor size, 
high nuclear grade, development of distant metastases and a reduced survival rate (Table 1) 
[5]. Moreover COX-2 expression correlates with aromatase expression. 
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An explanation for the variable findings of COX-2 protein expression may be caused by the 
different scoring systems and cut-offs used for COX-2 immunoreactivity.  
Half and co-workers [72] examined immonochemical human breast cell lines of normal and 
neoplastic breast tissue and detected a COX-2 expression in breast cancer cells in 43%, in 
DCIS in 62.5% and benign breast cells had a COX-2 expression in 81%. The more elevated 
COX-2 expression in DCIS in terms of a premalignant lesion might mean that an up-
regulation or over-expression of COX-2 occurs relatively early in the carcinogenesis of breast 
cancer [72]. Contrary to Half and co-workers [72], Denkert and co-workers [73] could not 
detect a COX-2 expression in benign breast tissue and this may support the partially 
conflicting data. Denkert and co-workers [73] detected a COX-2 expression in 41% in 
invasive ductal breast cancer, however detected it in only 14% of invasive lobular tumors 
and 21% in other breast carcinomas (Table1). The COX-2 expression was associated with 
positive axillary lymph nodes (>50% node positive, just 16% in node negative breast cancer), 
extensive tumor growth (58% in tumors >20mm, in 24% in tumors <20mm), poor nuclear 
grading, vascular invasion and hormone receptor negativity. 
Not all the studies have determined a correlation between COX-2 expression and 
clinicopathological parameters. Half and co-workers [72] could not demonstrate a 
significant correlation but Ristimäki and co-workers [74] certainly did show a significant 
correlation between COX-2 expression and hormone receptor negativity, extensive tumor 
growth, high nuclear grading and HER2 positivity. In a recently published paper by Singh-
Ranger and co-workers [75], a correlation to distant metastases was described and Nassar 
and co-workers [76] demonstrated a correlation to nuclear grading and tumor size; however 
a correlation to important clinical goals such as eradicating the disease and enhancing 
overall survival rate have not yet been found. 
Therefore COX-2 over-expression correlates in a different manner depending upon its 
aggressiveness the invasive potential of tumor cells, and then consequently exhibiting a 
higher incidence of distant metastases [40]. 
 
Refe-
rence 
N = COX-2 positive (%) 
Correlation of COX-2 expression and 
clinicopathological parameters 
  Carcinoma DCIS 
Benign 
tissue 
Angio-
genesis
HR-
status
HER2 Grading Age Node + 
Big 
tumor 
[77] 44 2/44 (4,5%) - - Not examined 
[78] 27 7/17 (42%) 8/10 (80%) - Not examined 
[72] 106 18/42 (43%) 10/16 (63%) 39/48 (81%) - No No - - - - 
[73] 221 80/221 (36%) - 0% Yes Yes - Yes No Yes Yes 
[79] 46 50% - - Yes No No No No Yes  
[74] 1576 589/1576 (37,4%) - - - Yes Yes Yes - Yes Yes 
[80] 106 90/106 (85%) - - No No No No No No No 
[81] 128 41% - - Yes - - Yes - Yes Yes 
[82] 192 40,6% - - - Yes Yes Yes - - Yes 
[83] 65 41/65 (63%) - - - Yes Yes - - - - 
[76] 43 41/43 (95%) - - - No No Yes - - Yes 
Table 1. Immunochemical examinations of COX-2 expression and correlation with selected 
clinicopathological parameters in breast tissue. 
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Transcriptional studies have also revealed a distinct variation in their results regarding 
COX-2 expression. The detection rate varies between 50 and 100% in the literature (Table 2).  
There is a comparable relationship between COX-2 immunoreactivity and mRNA 
expression in tumor tissue [77]. Zhao and co-workers [84] demonstrated an increased 
mRNA expression in hormone receptor positive breast cancer; a result that was confirmed 
by Singh and co-workers [85] in breast cancer with positive progesterone receptors. 
However, only a small number of studies have examined the correlation between mRNA 
expression and clinico-pathological parameters. These results are summarized in Table 2. 
 
Reference N = 
COX-2-mRNA 
positive (%) 
Clinicopathological correlation of COX-2 with 
   
Angio-
genesis 
HR-status HER2 Grading Age Node + 
Big 
tumor 
[86] 40 40/40 (100%) Not examined 
[72] 9 9/9 (100%) Not examined 
[87] 7 7/7 (100%) - - - - - - - 
[88] 20 10/20 (50%) - - - - - - - 
[85] 18 18/18 (100%) Not 
examined 
Yes (PR) 
 
Not examined 
[84] 30 27/30 (90%) - Yes (ER+) -  
Not examined 
Table 2. COX-2 mRNA expression and correlation with selected clinicopathological 
parameters in breast cancer. 
These results are contrary to the immunochemically evaluated data, which show an 
association to hormone receptor negative tumors. This could be explained because before 
the genetic information of COX-2 is translated into a biologically active protein, COX-2 
mRNA is post transcriptionally modified in the nucleus. Thus, we speculate that the COX-2 
mRNA is destabilised by its AU rich sequences and no COX-2 protein is generated. 
Therefore, the correlation between the hormone receptor status and COX-2 mRNA levels is 
not obvious in studies where the COX-2 protein expression was investigated [5]. There are 
some well known factors which affect the COX-2 mRNA levels like interleukin-1 stabilises 
the highly unstable COX-2 mRNA transcript [89], however steroids may destabilise the 
COX-2 mRNA [90]. Furthermore, it might be possible that genetically different subtypes of 
breast cancer express COX-2 and are then associated with both hormone receptor-negative 
and receptor-positive tumors [91]. Additionally, Ristimäki and co-workers [74] reported that 
hormone receptor-positive patients who express COX-2 had a poor survival rate. 
7.1 COX-2 and hormone receptors 
There is concurrent evidence about the interaction of PGE2/COX-2 and the estrogen 
receptor signalling pathway. For example, COX-2 expression is correlated with the 
expression of the aromatase [92] and in vitro studies support this data. It has been shown 
that COX-2 promotes the aromatase transcription, whereas COX-2 inhibitors diminish it 
[93]. Based on the elevated synthesis of prostaglandins in cells that express COX-2, the 
aromatase expression and activity is increased in breast cells [94, 95]. Expression of 
aromatase leads to estrogen production and from cell line studies; we know that hormone 
receptor expression can be induced by sex steroid hormones [96]. All the data supports the 
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close correlation between COX-2 and hormone receptors. Wolf and co-workers [70] reported 
a link between the estrogen signalling pathway and 15-PGDH by a negative feedback 
mechanism. High levels of this hormone reduced the 15-PGDH expression but the activity 
of the ERE (estrogen responsive element) and the activity of the aromatase increased.  
New studies suggest a synergism between selective COX-2 and aromatase inhibitors.  
7.2 Results from in vivo studies  
The impact of COX-2 in carcinogenesis of breast tumors has been shown in transgenic mice 
models [97]. It has been reported that the over-expression of COX-2 in breast tissues is 
associated with decreased BAX and Bcl-xL (pro apoptotic) and increased Bcl-2 (anti 
apoptotic) protein levels. Therefore, the author suggested that induction of carcinogenesis is 
COX-2 dependent [97]. In contrast, the resistance to apoptosis is associated with increased 
COX-2 levels [98]. The importance of COX-2 in correlation to the tumor formation has been 
investigated in COX-2 knockout mice. The COX-2 knockout mice lead to an 86% reduction 
of intestinal adenoids [99]. 
7.3 COX-2 and tumorigenesis 
The expression of COX-2 is regulated by post-transcriptional and -translational mechanisms. 
Different cytokines, growth factors and oncogenes have been shown to induce the COX-2 
expression which is associated with carcinogenesis [46, 100]. 
7.3.1 Influence of COX-2 on angiogenesis and apoptosis 
Angiogenesis is the development of new blood vessels and is an important factor in tumor 
proliferation, invasion and metastasis. Davies and co-workers [101] showed a significant 
positive correlation between COX-2 expression and the endothelial surface marker CD31. 
Other reports confirmed a positive correlation between COX-2 and the vascular endothelial 
growth factor (VEGF) [102, 103]. During carcinogenesis COX-2 modulates the 
neoangiogenesis and seems to stimulate the production of proangiogenic factors such as 
VEGF, basic fibroblast growth factor (bFGF), transforming growth factor 1 (TGF1), platelet 
derived growth factor (PDGF) and endothelin [104, 105]. The application of selective COX-2 
inhibitors decreased the angiogenesis in different vivo models [106]. Recently, an 
angiogenesis independent mechanism, so called Vasculogenic Mimicry (VM), was described 
where poorly differentiated breast cancer cells were nourished without the mechanisms of 
classic neoangiogenesis [107-109]. VM is a phenomenon of vessel formation of epithelial 
tumor cells without any participation of endothelial cells and itis a mechanism independent 
of or simultaneous to neoangiogenesis thus ensuring the tumor perfusion [110]. Hence, the 
VM might be an important factor for new antiangiogenic therapeutical approaches. The 
existence of VM in breast cancer patients is associated with a poor 5-year survival rate 
compared to patients without. [111]. Basu and co-workers [112] reported that highly 
invasive MDA-MB-231 breast cancer cells and the less invasive subtype MDA-MB-435 cells 
that over express COX-2, formed new micro vessels. In contrast, non-invasive MCF-7- and 
ZR-75-1-breast cancer cells which had a lower COX-2 expression did not. The application of 
the COX-2 inhibitor celecoxib (40 und 60 µmol/l, p>0.001), inhibits the formation of new 
vessels. This effect was restored with PGE2. This data was confirmed by an in vivo xenograft 
model. VEGF, GRO, IL-6, IL-8, TIMP1, TIMP2 were the main angiogenic proteins which 
were inhibited by celecoxib [112]. 
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7.4 Breast cancer and NSAIDs 
The rationale for using NSAIDs is their non-selective (ASS, ibuprofen etc.) or selective 
(COX-2 inhibitors such as celecoxib) suppression of the COX-system. In a meta-analysis 
consisting of 14 epidemiological studies (6 cohort studies and 8 case control studies) breast 
cancer risk was reduced by 18% due to constant intake of NSAIDs [113]. An extensive 
Canadian study including 5882 patients reported a reduction of breast cancer incidence by 
24% due to the NSAIDs intake for 2 – 5 years [58]. Another case control study demonstrated 
a 40% reduction after 5 years of NSAIDs intake [57]. These results seemingly justify the 
preventive use of NSAIDs, however, contrarian results were delivered by the Nurses Health 
Study. This trial showed no difference during the intake of ASS (100mg) in neither women 
with breast cancer nor in healthy women [114]. On the contrary it was in patients with colon 
cancer who led the continuous intake of NSAIDs to a reduction of incidence in 40-50% [56, 
115, 116]. 
Data of animal models supports the use of selective COX-2 inhibitors both for the 
therapeutic and preventive uses. For instance, the use of celecoxib in rats led to an 
averaged downsizing of breast tumor volume by 32%, however, a tumor volume 
enlargement of 518% was observed in the control group [117]. Harris and co-workers 
[118] examined the influence of celecoxib in 120 rats. Three groups of rats were formed. In 
one group the food was enriched with celecoxib. The other two groups obtained either 
ibuprofen or nothing. After seven days 7,12-Dimethylbenz(a)anthracene (DMBA) was 
applied intragastrically and the described food was continued for another 105 days. A 
distinct reduction in tumor incidence, variety and tumor volume was shown in the 
celecoxib treated group [118]. In a recently published paper Barnes and co-workers [119] 
could induce breast tumors in mice by injecting estrogen-positive MCF7/HER2-18- and 
estrogen-negative MDAMB231 breast cancer cells. The application of celecoxib resulted in 
a significant growth reduction of the MCF7/HER-18 tumors (58.7%) and the MDAMB231 
tumors (46.3%) in comparison to the control group. Therefore, celecoxib dropped the 
COX-2 expression and enhanced the apoptosis significantly [119]. Yoshinaka and co-
workers [120] also showed that the use of celecoxib significantly reduced tumor sizes, 
increased apoptosis and that a reduced DNA synthesis in the tumor tissue of mice 
induced breast carcinomas. Moreover the neoangiogenesis was influenced as VEGF-A-
mRNA levels were found to be reduced [120]. 
7.5 COX-2-inhibitors in systemic treatment 
Several studies have evaluated the significance of COX-2 inhibitors in combination with 
systemic treatment. A phase II study observed a clinical benefit of 47.5% for the combination 
of capecitabine and celecoxib in patients with metastatic breast cancer. The combination was 
well tolerated [121]. 
Recently published data about COX-2 and its significance on the aromatase and influence on 
the female hormonal balance are of strong interest. Besides finding an increased effect on 
estrogen synthesis in malignant breast tissue, a strong correlation between COX-2 and 
aromatase mRNA expression were found. This data supports the assumption that COX-2 is 
able to regulate aromatase activity in breast tissue [92]. A possible synergism between COX-
2 and aromatase-inhibitors is even more interesting and so a prospective randomised phase 
III multicenter trial (REACT-trial) was conducted that included primary breast cancer 
patients in order to evaluate the combination of celecoxib and exemestane, an aromatase 
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inhibitor, in an adjuvant setting. The combination of celecoxib and exemestane was already 
well tolerated and had shown a clinical benefit of 74% [122] or had led to a benefit extension 
(median 96.6 weeks vs. 49.1 weeks) in patients with metastatic breast cancer [123]. 
Other malignancies were also proven on the benefit of selective and non-selective COX-2 
inhibitors in combination with other compounds such as chemotherapy [124, 125], 
tyrosinekinase inhibitors [126] and other new approaches [127]. Some of them are 
encouraging, like the results of the ASCENT trial [124] and some are disappointing. Further 
work is required to establish how NSAIDs can be best applied for therapeutic benefit. 
8. Vitamin D 
8.1 Vitamin D metabolism 
Vitamin D, a secosteroid hormone, is assimilated by food (milk, fish, liver), multi-vitamin 
preparations and dietary supplements [128]. Vitamin D is also synthesised from 7-
dehydrocholesterol and provitamin D3 after skin exposure with sunlight (ultraviolet 
spectrum 290-315nm) [129]. Based on its animal or herbal origin, there are two existing 
vitamin D metabolites: cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) [17], 
which is less efficient in increasing the 25-hydroxyvitaminD [25(OH)2D3] serum levels 
[130]. Cholecalciferol attains to the liver through the bloodstream and is transformed to 
25(OH)2D3 (25-hydroxyvitamin D3, calcediol, 25-hydroxycholecalciferol) by a 
hydroxylation on the C25 position [131, 132]. 25(OH)2D3, a circulating metabolite, 
correlates with the vitamin D balance. The hydroxylation of cholecalciferol on the C25 
position is inadequately regulated. 25(OH)2D3 level increased with the vitamin D intake, 
therefore, the 25(OH)2D3 serum level is normally used as an indicator of the vitamin D 
balance [133]. The serum level range of 25(OH)2D3 is between 10 and 50 ng/ml and round 
about 30pg/ml for 1,25(OH)2D3 [134]. 25(OH)2D3 is renally converted to the biologically 
active metabolite 1,25-dihydroxycholecalciferol [1,25(OH)2D3] by the 1-α-hydroxylase 
(CYP27B1). 1,25(OH)2D3 is 100-1000 fold more active than the other natural metabolites 
[135]. The 1-α-hydroxylase, a mitochondrial enzyme, which belongs to the P450 enzyme 
family is located in the renal proximal tubule. Besides the renal expression of the enzyme, 
many studies reported an extra renal expression of 1-α-hydroxylase and thus an extra 
renal synthesis of 1,25(OH)2D3. This enzyme has been detected in many cell types and 
tissues, e.g. prostate, breast, lung, pancreas, parathyroid and monocytes [136]. The extra 
renal synthesised 1,25(OH)2D3 has cell specific functions and as a result acts as local auto- 
and paracrine factors. In this context, many extra renal effects of 1,25(OH)2D3, e.g. cell 
cycle arrest, induction of apoptosis and cell differentiation, have been reported [136]. The 
fine tuned activity of 1-α-hydroxylase correlates inversely with the calcium metabolism 
and thus the circulating levels of 1,25(OH)2D3 correlates inversely with the ingested 
amount of calcium [137]. 1,25(OH)2D3 Serum levels are maintained in pmol/l range by a 
classic negative feedback mechanism. The decrease of calcium or phosphate levels leads 
to an increase of the 1-α-hydroxylase activity and an enhanced synthesis of 1,25(OH)2D3 
which in turn promotes the intestinal resorption of calcium and phosphate and the 
calcium mobilisation from the bones. The activity of 1-α-hydroxylase decreased with 
increasing 1,25(OH)2D3 levels, which leads to 24 hydroxylase activation. This enzyme 
degrades 1,25(OH)2D3 to its inactive metabolite 24,25(OH)2D3 [138, 139], which is 
subsequently converted to calcitroic acid and excreted. Hence, the nutritive intake of  
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calcium directly regulates 1-α-hydroxylase activity and indirectly modifies parathormone 
levels. This hormone produced in the parathyroids increases the phosphate excretion in the 
proximal tubule but promotes the sodium, potassium and calcium resorbtion in the distal 
tubule. Under normocalcemic conditions, the activity of 1-α-hydroxylase is inhibited. These 
regulations are necessary to synthesize 1,25(OH)2D3 even though much is needed to cover 
the calcium and phosphate demand and to avoid a 1,25 (OH)2D3 intoxication [139]. The 
circulating vitamin D level depends on many different factors such as: the vitamin D content 
in either the ingested nutrition or the dietary supplements, and the endogenous production 
and degeneration via vitamin D metabolising enzymes. A simplified scheme of vitamin D 
metabolism is presented in figure (2). 
 
 
Fig. 2. Simplified scheme of the vitamin D metabolism. Vitamin D (food intake, synthesis in 
skin) is metabolised in liver to 25(OH)2D3, then via the renal 1-α-hydroxylase (endocrine 
signalling pathway or extra renal in tissues (autocrine/paracrine signalling pathway) to 
1,25(OH)2D3. 
8.2 Extrarenal vitamin D metabolizing enzymes 
The biologically active metabolite is produced after a series of hydroxylations through 
cytochrome P450 enzymes which belong to the cytochrome p450 super family. The different 
enzymes are handled as follows: 
nutrion / dietary supplements 
sunlight exposure
provitamin D3 
vitamin D3 
25-hydroxylase 
25(OH)2D3
25(OH)2D3
renal endocrine 
synthesis
25(OH)2D3 25(OH)2D3 
1α-hydroxylase 1α-hydroxyase
1,25(OH)2D31,25(OH)2D3 1,25(OH)2D3 
calcium and  
phosphatbalance 
cell differentiation, 
proliferation 
bloodstream
7-dehydrocholesterol 
liver  
(Calcidiol) 
(Calcitriol)
24-hydroxylase 
(Inactivation) 
apoptosis, cellcycle 
arrest, anti 
angiogenesis 
bones, thyroid 
intestinal tract 
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8.2.1 1-α-hydroxylase (CYP27B1)  
The 25-hydroxyvitamin-D3-[25(OH)2D3]1-α-hydroxylase (1-α-hydroxylase) is encoded by 
the CYP27b1 gene and catalyzes the synthesis of 1,25(OH)2D3 from 25(OH)2D3. 1,25(OH)2D3 
is the most important regulator of the enzyme that leads to a decreased enzyme expression. 
The regulation of the extra renal 1-α-hydroxylase depends on local factors like cytokines 
(interleukins, interferones and tumor necrosis) and growth. The optimal 1,25(OH)2D3-level 
tuning mechanism is not yet completely understood [139]. The reduced expression of the 
enzyme suggests the involvement of a negative vitamin D responsive element (VDRE) and 
Turunen and co-workers [140] showed that the enzyme’s response to 1,25(OH)2D3 is a cell 
specific event with participation of many VDREs. The suppression of cell proliferation, the 
induction of apoptotic events and the modulation of immune responses are counted among 
the classical features of 1,25(OH)2D3. After binding to the vitamin D receptor, 1,25(OH)2D3 is 
able to arrest the cell cycle of a tumor cell in the G1-G0 phase via specific mechanisms [139]. 
In prostate and colon cancer the tumor protective effects of vitamin D is correlated to 
vitamin D deficiency [141]. Much data reports that both the renal and extra renal 1-α-
hydroxylase are based on the expression of the same gene product. In contrast to the renal 1-
α-hydroxylase, the extra renal enzyme is not subjected to the auto regulation as mentioned 
above [136, 142]. Therefore the enzyme’s tissue specific expression might be a key 
mechanism in connecting the vitamin D metabolism to the anticarcinogenic effects of 
1,25(OH)2D3. 
Although the enzyme’s cytokine and growth factor related regulation is not completely 
understood, it has been shown that different cytokines stimulate the 1-α-hydroxylase in 
different cell types [139, 143-146]. Another potential mechanism of gene regulation is the 
incidence of different gene polymorphisms [147] and inactive variants due to alternative 
splicing of the 1-α-hydroxylase mRNA. But this mechanism’s function is not completely 
clarified. Alternative splicing within the post transcriptional modification is a normal 
process of gene expression in breast cancer cells and based on the pre mRNA, different 
mature mRNAs are generated when introns or exons are deleted or added. Thus, the 
translation of these mRNAs leads to different enzyme proteins, however, mis-spliced 
mRNAs are usually quickly degraded although it appears that this mechanism has failed in 
various cells. It has been reported that different protein variants of 1-α-hydroxylase might 
have diverse biological functions. Fischer and co-workers [148] showed 6 different variants 
of the enzyme in MCF10F via nested touchdown PCR, but in MCF-7, these variants 
appeared weakly expressed. Based on this data, the authors concluded that because 
alternative splicing regulates the level of the active enzyme extrarenaly it therefore regulates 
the local production of 1,25(OH)2D3 [149]. The activity of the extrarenally expressed 1-α-
hydroxylase is an important factor of the tumor pathophysiology because of an 
accumulation of 1,25(OH)2D3 in many tissues. Studies of prostate [150, 151], colon [152-154] 
and breast cancer [148, 155, 156] have shown the expression of 1-α-hydroxylase in healthy as 
well as in malignant tissues. Thus, 1,25(OH)2D3, which is produced extrarenally might have 
autocrine behaviour to protect cells against transformation and supports the suggestion of 
its carcinoprotective effects. Accordingly, low 1-α-hydroxylase levels correlate with the risk 
of prostate-, colon- [157] or breast cancer [158, 159]. Moreover, the extra renal production of 
1,25(OH)2D3 inhibits cell proliferation and promotes cell differentiation in xenograft models 
[160]. Besides the expression of the 1-α-hydroxylase in breast [155, 161], endometrial [162], 
cervical and ovarian carcinomas [163], the induction of the enzyme has also been shown in 
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lymphomas [164] and dysgerminomas [165]. In these reports, the local synthesis of 
1,25(OH)2D3  was mediated by the 1-α-hydroxylase expression of tumor associated 
macrophages. The expression of the enzyme mammary gland tissue occurs in lobules and 
ductus, primarily in the cancer tissue and invasive tumor cells and inflammatory infiltrate. 
Thus, it might be possible that the enzyme activity and the vitamin D receptor (VDR) 
expression are considerably higher than in the benign tissue compared to aggressive tumor 
cell lines (MCF-7res, MDA-MB231) [166]. Townsend and co-workers [166] compared breast 
cancer and benign tissue samples via reverse transcription PCR. They reported a 27-fold 
induction of the 1-α-hydroxylase expression and 7-fold induction of the VDR expression in 
tumor samples. Because 80% of the tumor tissues had an increased 1-α-hydroxylase und 
VDR, they concluded that there was a closed coupling of both gene products. These results 
are in compliance with Segersten and co-workers [161]. The capacity of 1-α-hydroxylase to 
synthesize 1,25(OH)2D3 within the mammary gland parenchyma results in, on the one hand, 
the available amount of 25(OH)2D3, and is dependent on sun light exposure and the season 
[167-170] - normally there is no definite correlation between 25(OH)2D3 and 1,25(OH)2D3 – 
yet on the other hand, the level of the extra renal production of 1,25(OH)2D3 is limited by the 
expression of the 1,25(OH)2D3- decomposing enzyme 24-hydroxylase, which is stimulated 
by 1,25(OH)2D3 in VDR expressing tissues. Based on the missing correlation of 24-
hydroxylase and VDR or the 1-α-hydroxylase in breast cancer tissues, it seems that 24-
hydroxylase is independently regulated. Kemmis and co-workers [171] demonstrated the 
expression of a functioning VDR and an inhibition of proliferation via 1,25(OH)2D3 in 
benign breast cells and MCF-7. The VDR expression in HMEC breast cells was higher than 
in MCF7 cells. Furthermore, the authors showed an expression of 25(OH)2D3 metabolizing 1-
α-hydroxylase and 24-hydroxylase in these cell types, whereas the 1-α-hydroxylase 
expression was higher in MCF-7. In contrast to renal HKC8 cells, the expression of 1-α-
hydroxylase was not inhibited by 1,25(OH)2D3. Based on the strong induction of the 24-
hydroxylase through the 1,25(OH)2D3 application, the authors showed that MCF7 cells were 
more sensitive in response to 1,25(OH)2D3 compared to HKC-8 and HMEC cells. From this 
data, they concluded that there is a functional vitamin D receptor as well as intact signalling 
transduction pathways in MCF-7 cells. The data suggests that the synthesis of 1,25(OH)2D3 
and the activation of the VDR inhibits the cell proliferation in breast cells. Thus, the 
treatment of benign breast cells with 25(OH)2D3 leads to an activation of the VDR 
transcription and the regulation of its target genes (CYP27B1, CYP24) and finally to an 
inhibition of cell proliferation. According to that, CYP27B1 lords it over CYP24 which means 
a transformation of 25(OH)2D3 to 1,25(OH)2D3. Kemmis and co-workers [171] have shown 
for the first time that physiological 1,25(OH)2D3 levels (30-100nmol/L) are able to inhibit cell 
proliferation in benign HMEC cells and in MCF7 breast cancer cells. Interestingly, aging 
process and the associated lack of estrogens correlate with decreased 25(OH)2D3 levels. The 
reason is that the ability of estrogen to stimulate the renal CYP27B1 activity [172]. 
Accordingly, the lack of estrogens leads to decreased 1,25(OH)2D3 levels and presents the 
highest risk for breast cancer in postmenopausal women [273]. 
8.2.2 24-hydroxylase (CYP24) 
The 25-hydroxyvitamine D3-24 hydroxylase (24-OHase, 24-hydroxylase) encoded by the 
CYP224 gene is induced by 1,25(OH)2D3 in breast cell lines where the enzyme is time and 
dose dependently stimulated by 1,25(OH)2D3 [174]. An increased enzyme expression in 
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ovarian, cervical and breast cancer compared to healthy tissue samples has been shown by 
immunochemistry and real time PCR [163]. In contrast, Townsend and co-workers [166] 
showed a 4-fold increase of the enzyme expression in malignant breast tissues compared to 
healthy tissue samples using the same technique. Additionally, the expression of 24 
hydroxylase increased in breast cancer cells foremost in hormone resistant MCF-7 Res and 
the aggressive MDA-MB231 cells compared to benign MCF-12A cells [166]. Kemmis and co-
workers [171] reported the highest 24 hydroxylase expression in MCF-7 cells and Segersten 
and co-workers [161] showed a 2-fold enzyme expression in tumor tissues compared to 
benign tissue samples. The authors concluded that the conversion of 1,25(OH)2D3 into the 
inactive metabolite 1,24,25(OH)3D3 is significantly higher in malignant tissues. Furthermore 
Townsend and co-workers [166] detected the enzyme only in breast cancers with an 
increased 1-α-hydroxylase and VDR expression. Further analysis showed that in a healthy 
tissue sample expression of 24-hydroxylase correlated with both 1α-hydroxylase and VDR. 
There was not such a correlation in breast tumors. Hypothetically, the 24 hydroxylase acts as 
a part of a well organized feedback mechanism and is transcriptionally modulated to 
increase the local 1,25(OH)2D3 and VDR level [166]. The synthesis of 1,25(OH)2D3 via the 1-
α-hydroxylase has been shown in benign and malignant mammary gland tissues but this 
mechanism’s efficiency in tumor tissues might be affected by a dysregulated 24 hydroxylase 
expression. 
8.3 Vitamin D-receptor (VDR / mVDR)  
The vitamin D receptor (VDR) is an ubiquitary expressed steroid hormone receptor. Like 
other steroid, thyroid and retinoid receptors, the VDR is a member of the nuclear hormone 
receptor family. The receptor binds to its ligand 1,25(OH)2D3, interacts with other receptors 
by dimerization and binds as homodimers or heterodimers to specific DNA sequences. So 
called vitamin D responsive elements (VDRE) recruit additional co-activators (such as SRC-
1, GRIP-1/TIF2, ACTR) and interact with the transcriptional processing order to initiate or 
inhibit the transcription of its target genes [25]. It is well known, that steroid receptors 
consist of different variants with distinct specificities. Sunn and co-workers [175] described 
an N-terminal variant of the VDR. 1,25(OH)2D3 mediates its genomic effects as a VDR ligand 
and via the directed binding to the VDRE [176]. Besides its function in bone metabolism and 
in the calcium/phosphate balance, the VDR interacts with different signalling pathways, 
e.g. with p21, a cyclin dependent kinase inhibitor which is involved in cell cycle regulation 
and inhibition of the cancer cell proliferation [26]. There are some suggestions about the 
existence of a membrane VDR (mVDR) [177]. The mVDR mediates its signals through the 
change of the intracellular calcium concentrations and through interactions with the protein 
kinase C and enzymes of the MAPK family [178-183]. Although the mVDR seems unrelated 
to the nuclear VDR, Marcinkowska and co-workers [184] reported an interaction of both 
receptors. The function of this mechanism is not clearly defined and the cloning of the 
mVDR has failed until today. 
Many studies reported that extra renal VDR expression is associated with the non-classical 
effects of 1,25(OH)2D3. The VDR expression has been shown in healthy breast tissues and in 
more than 80% of the breast cancer tissues [185]. The natural ligand of the VDR, 1,25(OH)2D3 
and many new developed synthetic vitamin D analogues inhibit cell proliferation and 
induce apoptosis in breast cancer cell lines [186, 187]. Furthermore, in animal models, 
vitamin D analogues retard the tumor growth and lead to a regression of breast tumors [12]. 
www.intechopen.com
 
Breast Cancer – Carcinogenesis, Cell Growth and Signalling Pathways 
 
648 
8.4 Vitamin D-receptor gene polymorphism 
The gene that encodes the VDR has various polymorphisms. It has been hypothesised that 
the genetic VDR polymorphism influences the breast cancer risk due to its potential effects 
on VDR gene expression and protein function [188, 189]. Many polymorphisms of the VDR 
gene have been identified and several, such as FOK1, Bsm1, APA1, TAQ1 and Poly(A) are 
well analysed [190, 191]. The studies that were conducted had conflicting results [191]. 
Curran and co-workers [192] showed a significant association of the VDR polymorphism 
APA1 und TAQ with the breast cancer risk. A significant increased breast cancer risk in 
women with the ff genotype FOK1 was observed by Chen and co-workers [193]. Sinotte and 
co-workers [194] detected a significant link between familial breast cancer disposition and 
FOK1. Other data came from Trabert and co-workers [195] who found a correlation between 
a higher breast cancer risk and the genotype Bsm1 bb in postmenopausal women although 
there is also published data without any evidence for a link between VDR polymorphisms 
and breast cancer risk [196-199]. An analysis of the last 13 published studies in which 
different VDR polymorphisms and its relation to breast cancer were examined leads to the 
suggestion that the modification of breast cancer risk is associated with certain VDR 
polymorphisms and therefore 1,25(OH)2D3 might modify the risk of breast cancer [200]. A 
recently published paper by McCullough and co-workers [201] presented certain VDR gene 
polymorphisms associated with a decreased breast cancer risk in women who ingested high 
doses of calcium (no calcitriol) concluding that nutritive influences might modify the link 
between gene polymorphisms and breast cancer. This data could shed light on breast cancer 
risk evaluation or could even be used in a predictive manner to answer the question about 
which women are strongly endangered to develop distant metastases.  
9. Calcium 
Like vitamin D, humans ingest calcium through food or dietary supplements. 99% of 
calcium is bound as hydroxyl phosphatide in bones and teeth [202]. Only 1% calcium is 
extracellularly located. Plasma levels of calcium (Ca2+) are limited by the intestinal 
absorption, the renal secretion and the reabsorption. Additionally, the skeletal calcium 
storage and resorption keep the plasma levels of calcium in a closed range (3.5–5mmol/l) 
[202]. 
10. Vitamin D, calcium and breast cancer risk 
10.1 Dietary and supplemental vitamin D intake 
For 1,25(OH)2D3 several studies have shown both an antiproliferative effect and an 
inhibition of angiogenesis in malignant and healthy breast cancer cells [17, 185, 203-206]. In 
mouse models, an increased intake of vitamin D led to the suppression of epithelial 
hyperproliferation and tumorigenesis of the mammary gland that was caused by rich 
nutrition [207, 208]. 
Last but not least, it has been proven by the First National Health and Nutrition 
Examination Survey Epidemiologic Follow-Up Study that sunlight exposure is inversely 
correlated with breast cancer risk [209, 210]. In this study, the female population in the 
north-eastern parts of the U.S. have a higher risk of contracting breast cancer compared to 
the other states of the U.S. This leads to the suggestion that sunlight induced vitamin D 
production has a positive influence in avoiding breast cancer [20]. 
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In contrast, in the Nurses’ Health Study, there was an inverse association between vitamin D 
intake and breast cancer risk among premenopausal women but no association among 
postmenopausal women [20]. Consistent with this observation, a study published a few 
years ago was based on the Cancer Prevention Study II Nutrition Cohort and observed no 
associations between breast cancer and total and dietary vitamin D intakes among 
postmenopausal women [211]. Another Italian study recently showed an inverse association 
between vitamin D intake (in the study >143 IU) and breast cancer in 2569 breast cancer 
patients [212]. Two other studies that concentrated on vitamin D deficiency and its 
susceptibility for breast cancer incidence approved that a deficiency conditional on nutrition 
in adolescence does not lead to an increased breast cancer risk [213, 214]. 
The proper dose of vitamin D remains unclear and a recommendation does not exist, 
however a meta-analysis gives evidence towards a dose of >400 IU per day to reduce breast 
cancer risk [213]. 
10.2 Role of vitamin D in breast cancer 
To date, there have been several epidemiologic studies of the association between vitamin D 
and breast cancer risk, however, their results have not been consistent. Several studies 
observed an association between 25(OH)2D3 plasma levels and breast cancer incidence [19, 
215-217]. The predictive value of 25(OH)2D3 plasma levels depends upon the time they have 
been measured. Plasma levels that have been measured within a few years before breast 
cancer diagnosis are less predictive than plasma level measured many years before [217]. 
Furthermore, plasma levels that have been measured around 15 years before diagnosis do 
not have any aetiological value for the genesis of breast cancer [216]. 
Bertone-Johnson and co-workers [217] found a marginally significant reduction of breast 
cancer risk in women >60 years who had elevated 25(OH)2D3 and 1,25(OH)2D3 plasma 
levels. In contrast, published data by Shin and co-workers [20] demonstrated a significantly 
decreased breast cancer incidence in premenopausal, but not in postmenopausal women, 
who had continuous vitamin D intake. 
Furthermore, a case control study observed that women with plasma 25(OH)2D3 
concentration <50nmol/l had >5 times higher risk of breast cancer than those with plasma 
concentrations exceeding >150 nmol/l [158]. Janowsky and co-workers [19] also showed an 
inverse association between 1,25(OH)2D3 plasma levels to the point of diagnosis and breast 
cancer risk in patients with breast cancer. However, there was no difference in 1,25(OH)2D3 
plasma levels between patients with breast cancer and those with DCIS. The authors 
suggested that the grade of invasion was not correlated with the extent of 1,25(OH)2D3 level. 
Another nested case-control study with 96 breast cancer cases and 96 controls found no 
association between prediagnostic 1,25(OH)2D3 levels and levels at the time of diagnosis and 
breast cancer risk among postmenopausal women [216]. 
The circulating concentration of 25(OH)2D3 is considered to be an excellent measure of the 
availability of vitamin D from the diet, supplements and from synthesis in the skin [218]. Its 
potential importance in breast carcinogenesis is due to the fact that 25(OH)2D3 can be 
metabolised to 1,25(OH)2D3 by 1-α-hydroxylase in breast tissue [155]. Thus, 25(OH)2D3 
levels may be more representative of intracellular levels of 1,25(OH)2D3 than circulating 
levels of 1,25(OH)2D3 [217]. 
To date, no studies have been published investigating intracellular or tissue levels of 
1,25(OH)2D3 and 25(OH)2D3 in association with breast cancer risk.  
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10.3 Dietary and supplemental calcium intake 
Many studies about the importance of calcium and its association to breast cancer have 
already been published. Most of them are case-control studies and nearly all of them are 
relatively small and there is insufficient documentation regarding risk factors for breast 
cancer in multivariate analyses. 
Calcium is participating on carcinogenesis via regulation of cell proliferation, differentiation 
and apoptosis [219-221]. Cell proliferation and differentiation of breast cells can be increased 
by elevated calcium levels [208, 222, 223]. Boyapati and co-workers [224] observed a non-
significant inverse association between calcium intake and breast cancer risk among pre- 
and postmenopausal women but the Nurses’ Health Study has shown this association only 
for premenopausal women [20]. 
The anti-carcinogenic effects of calcium are last but not least, mediated by vitamin D, 
therefore calcium is one of the key mediators of the vitamin D induced apoptosis in breast 
cancer cells [208].  
11. Calcitriol and prostaglandins in cancer 
The stimulation of the renal calcitriol [1,25(OH)2D3] synthesis in vitro is well known as well 
as the inhibition of acetysalicylic acid as a non-selective NSAID [225]. This justifies the 
clinical use of NSAIDs in treating arthritis for example. Hayes and co-workers [226] 
observed an inhibition of calcitriol synthesis caused by PGE1 and PGE2 in synovial fluid 
macrophages from arthritic joints and with that he proved the link between vitamin D and 
prostaglandin metabolism. Several published studies have proven the anti-carcinogenic 
effects shown in different signalling pathways on prostate cancer cells [227-229]. The team 
around David Feldman examined the influence of calcitriol in established human prostate 
cancer cell lines (androgen dependent LNCaP cells and androgen independent PC-3 cells) 
and in primary normal prostatic epithelial cells derived from normal and cancerous human 
prostate tissue. They showed that calcitriol regulates biologically active prostaglandin levels 
and prostaglandin actions by three mechanisms: calcitriol suppresses the COX-2 expression 
and moreover it up-regulates the expression of 15-PGDH. This dual influence of calcitriol 
was associated with a decrease of PGE2 secretion in prostate cancer cells. Calcitriol reduces 
the mRNA expression of prostaglandin receptors EP2 and FP, additionally a mechanism to 
inhibit the biological activity of prostaglandins. 
The combination of calcitriol and NSAIDs led to a significant growth inhibition in prostate 
cancer cells via its synergistic effects. These findings might postulate that calcitriol and 
NSAIDs are definitely a useful combination in chemo preventive and/or therapeutic 
strategies in prostate cancer [230]. Unpublished own data support these results as we 
showed an inverse correlation between VDR- and COX-2 expression in breast cancer cells 
and a downregulation of COX-2 and an upregulation of 15 PGDH by calcitriol. Therefore we 
propose that these findings and suggest a possible link between VDR, associated target 
genes and the prostaglandin metabolism. 
12. Concluding remarks 
In conclusion, there is promising preclinical data inhibiting COX-2 in breast cancers, 
therefore the chance exists to innovatively disturb carcinogenesis of those gynecological 
oncological neoplasms Phase II trials have already been conducted to clear the safety of a 
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celecoxib treatment in metastatic breast cancer. Furthermore, calcitriol and calcium have 
shown anti-carcinogenic effects in experimental studies and several epidemiological 
studies have demonstrated an inverse association between vitamin D and calcium intake 
and breast cancer. Other studies have detected an inverse association between plasma and 
serum levels and breast cancer risk. Experimental studies support the hypothesis that the 
reduction of breast cancer risk is more significant among premenopausal women than 
among postmenopausal women and mPGES-1 and EP receptors might be important 
targets for the development of new anti inflammatory and antiproliferative tumor 
therapies. 
Questions that remain unanswered are: has calcitriol as antiproliferative effects in breast 
cancer as was proven in prostate cancer? Does a link exist between vitamin D and 
prostaglandin metabolism in breast cancers? These questions have to be answered as the 
increasing incidence of breast cancer have yet to be solved. Innovative treatment strategies 
fall on fruitful ground. Thus we need further studies that elucidate the importance of COX-2 
inhibitors in the preventive as well as in the adjuvant settings in breast cancers and finally 
that will evaluate the promising importance in the neoangiogenesis in detail. 
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14. Abbreviations 
bFGF  = basic fibroblast growth factor 
COX  = cyclooxygenase 
DCIS   = ductal carcinoma in situ 
DMBA  = Dimethylbenz(a)anthracene 
ER  = estrogen receptor 
ERE  = estrogen responsive element 
FIGO  = Fédération Internationale de Gyneécologie et d’Obstétrique 
GRO  = growth related protein 
HER2  = human epidermal growth factor receptor 2 
IL  = interleukin 
NSAID  = non-steroidal anti-inflammatory drug 
mPGES-1 = microsomalmicrosomal prostaglandin E synthase-1 
mRNA  = messenger ribonucleic acid 
PCR  = polymerase chain reaction 
PDGF  = platelet derived growth factor 
PG  = prostaglandin 
PGDH  = prostaglandin dehydrogenase 
PPAR  = peroxisomes proliferator-activated receptor 
TGF1  = transforming growth factor 1 
TIMP  = tissue inhibitor of matrix metalloproteinase 
VDR  = vitamin D receptor 
VDRE  = vitamin D responsive element 
VEGF  = vascular endothelial growth factor 
VM  = vasculogenic mimicry 
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